ArticleBMC cancer2022

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.

Lihong An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.